Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Kisqali - labeled renal guidance
Product / population
Ribociclib (Kisqali), oral tablets for adult breast cancer
Renal method
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
DailyMed SPL version 28, effective 2026-07-01; posted Jul 13, 2026
All record notes are retained here, including notes about sources not selected in this review.
Kisqali - product and source limitations
The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
What to reconcile: The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
Renal guidance: 2, dosage modification for severe renal impairment; 8.7
For severe renal impairment, start at 200 mg once daily on the prescribed treatment days. Mild or moderate impairment does not require renal adjustment. Retain the indication-specific treatment cycle, ECG and electrolyte monitoring. Do not interpret a daily dose as continuous 28-day administration.
RDM73-kisqali-official-1 · Source locator: Renal guidance: 2, dosage modification for severe renal impairment; 8.7
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
